Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based specialty injectables company Sagent Pharmaceuticals has closed a $30 million extension to the $53 million Series A financing of 2007. The round was led by Vivo Ventures.
Subscribe to our email newsletter
Proceeds from the financing will be used to fund near-term product launches, product development activities and strategic business initiatives.
Jeffrey Yordon, CEO, founder and chairman of the board of Sagent Pharmaceuticals, said: “This additional financing round will allow us to advance additional products to market and to avail ourselves of compelling, recently discovered product acquisition opportunities.”